Uccc-Gyn-20-01- Phase I Study Of Adjuvant Hypofractionated Whole Pelvis Radiation Therapy In Endometrial Cancer.
Posted Date: May 20, 2021
- Investigator: Teresa Meier
- Specialties: Cancer, Gynecologic Oncology, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the safety of adjuvant hypofractionated whole pelvis radiation therapy (WPRT) in endometrial cancer. The primary objective of the study is to determine the maximum tolerated dose per fraction (MTDF), defined by acceptable acute clinician-reported GI and GU toxicity and patient-reported GI toxicity, of WPRT from among the two study dose levels
Criteria:
Must Have Histologically Confirmed Stage I, Ii, Or Iii Endometrial Cancer That Requires Pelvic Radiation, Ecog 0-2, Must Have Undergone Total Hysterectomy And Bilateral Salpingo-Oophorectomy With Or Without Pelvic And/Or Para-Aortic Lymph Node Dissection/
Keywords:
Endometrial Cancer, Gynecology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com